Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

27. Januar 2016 08:00 ET | Quelle: Societal CDMO, Inc.

Recro Pharma Initiates Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain

MALVERN, Pa., Jan. 27, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the...
14. Januar 2016 13:19 ET | Quelle: Societal CDMO, Inc.

Recro Pharma to Present at NobleCon12 Investor Conference

MALVERN, Pa., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the...
06. Januar 2016 07:00 ET | Quelle: Societal CDMO, Inc.

Recro Pharma Reports Positive Top-Line Results for Phase II Clinical Trial of IV Meloxicam

IV Meloxicam Well Tolerated with Statistically Significant Analgesic Effect Reported Company on Track to Initiate Pivotal Phase III in 1Q 2016 MALVERN, Pa., Jan. 06, 2016 (GLOBE NEWSWIRE) --...
02. Dezember 2015 07:00 ET | Quelle: Societal CDMO, Inc.

Recro Pharma Appoints Stewart McCallum, MD, as Chief Medical Officer

MALVERN, Pa., Dec. 2, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of...
24. November 2015 07:00 ET | Quelle: Societal CDMO, Inc.

Recro Pharma to Present at the 2015 Piper Jaffray Healthcare Conference

MALVERN, Pa., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of...
13. November 2015 07:00 ET | Quelle: Societal CDMO, Inc.

Recro Pharma Reports Third Quarter 2015 Financial Results

MALVERN, Pa., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of...
12. November 2015 07:00 ET | Quelle: Societal CDMO, Inc.

Recro Pharma to Participate in Upcoming Investor Conferences

MALVERN, Pa., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of...
26. Oktober 2015 08:00 ET | Quelle: Societal CDMO, Inc.

Recro Pharma Provides Pipeline Update

IV Meloxicam Advancing to Phase III; Pivotal Trials Expected to Commence in First Quarter 2016 Company Shifts Focus of Dex-IN to Peri-Procedural Pain Indication MALVERN, Pa., Oct. 26, 2015...
10. September 2015 13:41 ET | Quelle: Societal CDMO, Inc.

Recro Pharma Appoints Karen A. Flynn to Its Board of Directors

MALVERN, Pa., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment...
10. September 2015 07:00 ET | Quelle: Societal CDMO, Inc.

Recro Pharma Announces Presentations at PAINWeek 2015

MALVERN, Pa., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment...

Vorherige Seite